Published in AIDS Weekly, August 22nd, 2005
The first poster presented results from the recently completed extension of the phase 2 study, known as REMIT, which showed that treatment with Remune was effective in delaying virologic failure during antiretroviral treatment interruption. Patients receiving the greatest number of injections showed the longest time to reach a failure endpoint....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.